Global Tissue Diagnostics Market, By Product (Consumables and Instruments), Technology (Immunohistochemistry, In Situ Hybridization, Digital Pathology and Workflow Management, and Special Staining), Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer, and Other Diseases), End User (Hospitals, Pharmaceutical Companies, Research Laboratories, Diagnostic Centres, Ambulatory Surgical Centres, and Others) – Industry Trends and Forecast to 2031.
Tissue Diagnostics Market Analysis and Size
The tissue diagnostics market is driven by advancements enabling accurate identification of diseases from organ and tumor tissues. It is used in the diagnosis and assessment of various diseases, including cancer, infectious diseases, autoimmune disorders, and genetic conditions. Also, the key players of this market invest in research and development to innovate diagnostic techniques, enhancing market competitiveness. For instance, Roche Diagnostics invested in developing advanced tissue diagnostic solutions, such as the VENTANA PD-L1 (SP142) Assay. This assay aids in diagnosing certain types of cancer and predicting response to immunotherapy, boosting the market growth.
Global tissue diagnostics market size was valued at USD 565.62 million in 2023 and is projected to reach USD 943.15 million by 2031, with a CAGR of 6.6 % during the forecast period of 2024 to 2031. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, import/export analysis, pricing analysis, production consumption analysis, patent analysis, and consumer behavior.
Tissue Diagnostics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Consumables and Instruments), Technology (Immunohistochemistry, In Situ Hybridization, Digital Pathology and Workflow Management, and Special Staining), Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer, and Other Diseases), End User (Hospitals, Pharmaceutical Companies, Research Laboratories, Diagnostic Centres, Ambulatory Surgical Centres, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Danaher (U.S.), Thermo Fisher Scientific (U.S.), Abbott (U.S.), Agilent Technologies Inc. (U.S.), Merck KGaA (U.S.), Sakura Finetek Japan Co. Ltd. (U.S.), BD (U.S.), QIAGEN (Germany), Bio SB (U.S.), BioGenex. (U.S.), Abcam Limited (U.K.), Cell Signaling Technology Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), The Menarini Group (Italy), Enzo Life Sciences, Inc. (U.S.), Zenalux Biomedical, Inc. (U.S.), Lunaphore Technologies SA. ((Switzerland), 3DHISTECH Ltd. (Hungary), Lunaphore Technologies (Switzerland), Biocare Medical, LLC. (U.S.), ., and Genomic Health Inc.(U.S.) among others
|
|
Market Opportunities
|
|
Market Definition
Tissue diagnostics involves examining tiny samples of body tissues to identify diseases such as cancer. Doctors take tissue samples through biopsies or surgeries. These samples are then analyzed under a microscope to look for abnormal cells or structures. Tissue diagnostics helps doctors make accurate diagnoses and determine the best treatment options for patients.
Tissue Diagnostics Market Dynamics
Drivers
- Rising Demand for Diagnostic Testing Services
With aging populations and changing lifestyles contributing to the growing disease burden, there is an urgent need for effective diagnostic solutions. This surge in demand, reflected in the expanding cancer market size, underscores the importance of early detection for successful treatment outcomes. Tissue diagnostics through techniques such as biopsies and molecular testing, plays a pivotal role in accurately identifying cancer types and guiding treatment decisions.
For instance,
- GRAIL has initiated non-invasive blood tests that analyze circulating tumor DNA, allowing for the detection of cancer at its earliest stages. This breakthrough technology showcases the critical role of tissue diagnostics in improving cancer detection rates and treatment outcomes
As a result, the market for tissue diagnostics continues to expand rapidly to meet the rising healthcare demands worldwide.
- Growing Demand for Personalized Medicine
The growing demand for personalized medicine is driven by advancements in molecular and genetic technologies, enabling tailored treatment strategies based on individual patient characteristics. This approach considers genetic makeup, lifestyle factors, and disease biomarkers to optimize treatment efficacy and minimize adverse effects. Patients increasingly seek personalized therapies that offer higher efficacy rates and fewer side effects compared to traditional treatments.
For instance,
- Foundation Medicine has created comprehensive genomic profiling tests that analyze tumor DNA to identify specific mutations and guide treatment decisions. This approach enables oncologists to prescribe personalized therapies tailored to the patient's unique genetic profile, leading to improved treatment outcomes and patient satisfaction
In addition, healthcare providers recognize the potential cost savings and improved patient outcomes associated with personalized medicine, further fueling its adoption and driving market growth in the healthcare industry.
Opportunities
- Strategic Collaborations and Partnerships with Healthcare Providers
Pharmaceutical companies often collaborate with biotechnology firms or academic institutions to access novel technologies, drug candidates, or research insights. Similarly, diagnostic companies may form partnerships with healthcare providers or data analytics firms to enhance diagnostic accuracy and expand market reach.
For instance,
- AstraZeneca partnered with Merck & Co. to develop and commercialize Lynparza (olaparib) as a potential treatment for multiple cancer types. This collaboration combines AstraZeneca's expertise in oncology with Merck's global reach, accelerating drug development and expanding patient access to advanced cancer treatments
These collaborations facilitate the development of new therapies, diagnostic tools, and treatment approaches, ultimately benefiting patients by improving healthcare outcomes. Furthermore, strategic alliances enable companies to navigate regulatory challenges more effectively, accelerate product development timelines, and capitalize on emerging market opportunities, thereby driving growth and competitiveness in the tissue diagnostic sector.
- Increasing Geriatric Population Impacts Demand for Tissue Diagnostics
As individuals age, they become more susceptible to various diseases, including cancer and degenerative conditions. Tissue diagnostics play a crucial role in diagnosing these age-related illnesses, enabling early detection and personalized treatment strategies. With a growing number of elderly individuals requiring diagnostic services, the demand for tissue diagnostics rises accordingly. This demographic trend drives market growth in the tissue diagnostics sector, highlighting the importance of catering to the healthcare needs of aging populations.
Restraints/Challenges
- Infrastructure Limitations in Developing Regions
Infrastructure limitations in developing regions, such as inadequate laboratory facilities, unreliable electricity supply, and limited access to specialized equipment, hinder the effectiveness of tissue diagnostics. Without proper infrastructure, tissue samples may be mishandled or improperly stored, leading to inaccurate results Limited access to reliable electricity, clean water, and proper waste disposal facilities further hinders the implementation of tissue diagnostics technologies. As a result, healthcare providers struggle to offer timely and accurate diagnostic services, leading to delays in diagnosis, treatment, and disease management. Additionally, infrastructure constraints impede the penetration of tissue diagnostics solutions into these regions, limiting market growth opportunities and exacerbating healthcare disparities between developed and developing economies.
- Lack of Skilled Personnel for Analyzer Operation
Advanced diagnostic analyzers require specialized training and expertise to operate effectively, interpret results accurately, and troubleshoot technical issues. However, the shortage of skilled personnel hampers the adoption and utilization of these sophisticated technologies, leading to suboptimal performance and reduced efficiency in diagnostic laboratories. This constraint not only impedes the timely delivery of diagnostic services but also limits the market potential for tissue diagnostics solutions, as healthcare facilities may struggle to fully leverage the benefits of these innovative tools without adequately trained staff.
This tissue diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global Tissue Diagnostics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In May 2022, Leica Biosystems (Nussloch, Germany) launched a compact, dual-retort tissue processor, the HistoCore PEGASUS Plus. Its compact design and dual-retort system enhance laboratory workflow, improving efficiency and throughout. This innovation drives the adoption of tissue processing technology, stimulating market expansion and innovation
- In March 2021, Roche launched DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research In March 2021, Roche launched DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research. This innovative kit enhances researchers' ability to detect multiple biomarkers simultaneously, advancing understanding and diagnosis of cancer, thereby driving demand for immunohistochemistry solutions and fostering market expansion
Tissue Diagnostics Market Scope
The tissue diagnostics market is segmented into four notable segments based on product, technology, disease, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Consumables
- Instruments
Technology
- Immunohistochemistry
- In Situ Hybridization
- Digital Pathology and Workflow Management
- Special Staining
Disease
- Breast Cancer
- Gastric Cancer
- Lymphoma
- Prostate Cancer
- Non-Small Cell Lung Cancer
- Other Diseases
End User
- Hospitals
- Pharmaceutical Companies
- Research Laboratories
- Diagnostic Centres
- Ambulatory Surgical Centres
- Others
Tissue Diagnostics Market Regional Analysis/Insights
The tissue diagnostics market is analysed and market size insights and trends are provided by based on product, technology, disease, and end user as referenced above.
The countries covered in the tissue diagnostics market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America dominates the tissue diagnostics market because of the rising prevalence of cancer in the region and growing investment in healthcare infrastructure. The presence of several public programs aims to minimize cancer incidences and raise the demand for cancer diagnosis in the regional market. The Cancer Prevention and Control Research Network is a flagship program by the Centers for Disease Control and Prevention that focuses on cancer prevention in this region.
Asia-Pacific is expected to be the fastest-growing region in the tissue diagnostic market due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The tissue diagnostics market also provides you with a detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the tissue diagnostics market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the tissue diagnostics market. The data is available for the historic period 2016-2021.
Competitive Landscape and Tissue Diagnostics Market Share Analysis
The tissue diagnostics market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the tissue diagnostics market.
Some of the major players operating in the tissue diagnostics market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Danaher (U.S.)
- Thermo Fisher Scientific (U.S.)
- Abbott (U.S.)
- Agilent Technologies Inc. (U.S.)
- Merck KGaA (U.S.)
- Sakura Finetek Japan Co. Ltd. (U.S.)
- BD (U.S.)
- QIAGEN (Germany)
- Bio SB (U.S.)
- BioGenex. (U.S.)
- Abcam Limited (U.K.)
- Cell Signaling Technology Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- The Menarini Group (Italy)
- Enzo Life Sciences, Inc. (U.S.)
- Zenalux Biomedical, Inc. (U.S.)
- 3DHISTECH Ltd. (Hungary)
- Lunaphore Technologies SA. (Switzerland)
- Biocare Medical, LLC. (U.S.)
- Genomic Health, Inc. (U.S.)
SKU-